VCP Scanner
ScreenerTechnicalBreakoutsThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistPricing
ScreenerTechnical ScannerBreakoutsThemes
Earnings
WatchlistPricing
Ctrl K
HALO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
HALOHalozyme Therapeutics, Inc.
$98.66$11.7B
Overview & Verdict
OverviewVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksHALOBalance Sheet

Halozyme Therapeutics, Inc. (HALO) Balance Sheet

25Y historyFree accessUpdated daily

Total debt increased to $2.1B in 2026Q2, pushing D/E to 14.95, while equity fell to $143.5M due to aggressive buybacks and acquisition-related charges, indicating a strained capital structure despite strong cash generation.

HALO Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01
Total Current Assets933.02M825.21M1.09B746.42M739.01M926.29M554.76M543.44M427.85M510.37M256.53M171.77M161.32M95.2M131.03M63.99M89.5M74.44M74.01M101.18M45.59M20.11M16.15M47.52K97.25K26.13K
Cash & Short-Term Investments231M142.82M596.07M336M362.79M740.92M368.01M421.26M354.53M469.21M204.98M108.34M135.62M71.5M99.9M52.83M83.26M67.46M63.72M97.68M44.19M19.13M16.01M47.52K97.25K26.13K
Cash Only163.14M133.82M115.85M118.37M234.19M118.72M147.7M120.18M57.94M168.74M66.76M43.29M61.39M27.36M99.9M52.83M83.26M67.46M63.72M97.68M44.19M19.13M16.01M47.52K97.25K26.13K
Short-Term Investments67.86M9M480.22M217.63M128.6M622.2M220.31M301.08M296.59M300.47M138.22M65.05M74.23M44.15M000000000000
Accounts Receivable455.83M441.27M308.45M234.21M231.07M90.97M97.73M59.44M30M22.13M15.68M32.41M9.15M9.1M15.7M2.26M2.33M4.24M7.26M779.83K0413.83K0000
Days Sales Outstanding93.3115.33110.89103.09127.7774.9133.3110.772.1225.5239.0287.5944.3360.59135.4214.7262.38113.31302.5474.91-1.19K----
Inventory137.13M176.47M141.86M127.6M100.12M53.91M60.75M29.36M22.63M5.15M14.62M9.49M6.41M6.17M2.67M567.26K193.42K1.16M441.32K703.47K442.49K278.96K51.82K000
Days Inventory Outstanding164.59210.89324.8242.12262.34241.69511.28235.28814.7360.29160.74118.43102.86360.57890.72803.0471.651.36K484.721.07K369.61.96K----
Other Current Assets109.06M64.64M38.95M48.61M45.02M000000000000000000-456.06K00
Total Non-Current Assets1.64B1.7B978.14M986.85M1.1B178.14M25.16M22.44M12.4M9.57M4.98M10.02M4.66M6.6M3.7M1.77M1.85M2.71M2.55M2.28M497.77K404.08K258.05K000
Property, Plant & Equipment84.27M82.14M75.03M74.94M75.57M8.79M10.59M10.86M7.46M3.52M4.26M3.94M2.95M3.42M3.7M1.77M1.85M2.71M2.55M2.28M497.77K381.25K235.5K000
Fixed Asset Turnover20.79x17.00x13.53x11.06x8.74x50.41x25.26x18.06x20.34x89.95x34.40x34.25x25.53x16.02x11.44x31.67x7.38x5.05x3.44x1.66x1.97x0.33x----
Goodwill581.73M580.36M416.82M416.82M409.05M000000000000000000000
Intangible Assets922.44M981.47M401.83M472.88M546.65M000000000000000000000
Long-Term Investments00000500K00000000000000000000
Other Non-Current Assets55.94M56.15M80.6M17.82M26.8M13.41M14.57M11.58M4.93M6.05M719K6.07M1.71M3.18M400K00000022.84K22.54K000
Total Assets2.58B2.53B2.06B1.73B1.84B1.1B579.92M565.87M440.25M519.95M261.51M181.79M165.98M101.79M134.73M65.76M91.35M77.15M76.56M103.46M46.09M20.51M16.4M47.52K97.25K26.13K
Asset Turnover0.67x0.55x0.49x0.48x0.36x0.40x0.46x0.35x0.34x0.61x0.56x0.74x0.45x0.54x0.31x0.85x0.15x0.18x0.11x0.04x0.02x0.01x-0.54x0.90x0.94x
Asset Growth %74.42%22.38%19.05%-5.88%66.74%90.44%2.48%28.54%-15.33%98.82%43.86%9.53%63.05%-24.45%104.88%-28.01%18.4%0.77%-26%124.47%124.72%25.03%34421.69%-51.14%272.22%-
Total Current Liabilities344.44M177.09M139.1M112.49M130.79M117.15M421.38M85.64M149.36M131.33M54.59M62.46M24.33M25.45M18.95M17.3M15.34M14.4M14.22M8.86M4.25M2.3M1.58M37.45K10.43K3.29K
Accounts Payable23.61M20.9M10.25M11.82M17.69M1.54M1.93M6.43M4.08M7.95M3.58M4.5M3M3.13M2.27M7.56M3.82M2.82M6.67M3.06M2.02M1.38M1.49M32.7K00
Days Payables Outstanding18.5924.9723.4722.4246.366.9116.2351.56146.8993.1239.3356.1548.22183.21757.6410.7K1.42K3.3K7.32K4.64K1.69K9.69K-442.02--
Short-Term Debt208.97M00013.33M89.42M397.23M19.54M91.51M77.21M17.39M21.86M00000000000000
Deferred Revenue (Current)00003.25M1.75M1.75M4.01M4.25M6.57M4.79M9.3M7.37M7.4M8.89M4.13M2.92M5.49M3.55M3.31M1.22M254.14K0000
Other Current Liabilities0156.19M00-3.25M000000000000000000010.43K3.29K
Current Ratio2.71x4.66x7.80x6.64x5.65x7.91x1.32x6.35x2.86x3.89x4.70x2.75x6.63x3.74x6.92x3.70x5.83x5.17x5.21x11.41x10.73x8.73x10.22x1.27x9.32x7.94x
Quick Ratio2.31x3.66x6.78x5.50x4.88x7.45x1.17x6.00x2.71x3.85x4.43x2.60x6.37x3.50x6.77x3.67x5.82x5.09x5.17x11.33x10.62x8.61x10.19x1.27x9.32x7.94x
Cash Conversion Cycle239.3301.24412.22322.79343.75309.68628.36294.42739.96-7.31160.42149.8798.97237.96268.49-9.88K-1.28K-1.83K-6.54K-3.5K--6.55K----
Total Non-Current Liabilities2.09B2.3B1.56B1.54B1.54B790.33M7.49M388.47M42M180.25M239.41M76.33M100.29M96.33M66.93M37.56M55.65M55.85M46.96M36.83M18.76M00000
Long-Term Debt1.94B2.14B1.51B1.5B1.49B787.25M0383.05M34.87M125.14M199.23M27.97M49.86M49.77M29.66M00000000000
Capital Lease Obligations000000000000001.45M00000000000
Deferred Tax Liabilities147.73M42.92M00000000000794.78K-1.45M00000000000
Other Non-Current Liabilities102.68M113.86M54.76M37.72M45.91M544K3.47M4.18M2.12M814K358K4.44M3.17M1.36M861.88K802.01K474.39K859.83K1.07M36.83M18.76M00000
Total Liabilities2.43B2.48B1.7B1.65B1.67B907.48M428.88M474.11M191.36M311.58M294M138.79M124.63M121.78M85.87M54.86M70.99M70.25M61.18M45.69M23.01M2.3M1.58M37.45K10.43K3.29K
Total Debt2.15B2.14B1.51B1.5B1.51B876.67M397.23M402.59M126.38M202.35M216.62M49.83M49.86M49.77M31.11M00000000000
Net Debt1.98B2.01B1.39B1.38B1.27B757.96M249.53M282.41M68.44M33.61M149.86M6.54M-11.53M22.41M-68.79M-52.83M-83.26M-67.46M-63.72M-97.68M-44.19M-19.13M-16.01M-47.52K-97.25K-26.13K
Debt / Equity14.95x43.89x4.14x17.89x8.87x4.45x2.63x4.39x0.51x0.97x-1.16x1.21x-0.64x-----------
Debt / EBITDA2.09x2.37x2.38x3.55x4.75x3.14x2.69x--2.43x----------------
Net Debt / EBITDA1.93x2.22x2.20x3.27x4.01x2.72x1.69x--0.40x----------------
Interest Coverage34.31x26.76x31.79x19.57x15.69x34.02x7.35x-5.21x-3.84x3.68x-4.10x-5.20x-11.25x-24.50x------------
Total Equity143.54M48.81M363.82M83.81M169.8M196.95M151.05M91.77M248.89M208.37M-32.48M43M41.35M-19.99M48.85M10.9M20.35M6.9M15.38M57.77M23.08M18.21M14.82M10.06K86.81K22.84K
Equity Growth %-186.59%-86.58%334.11%-50.64%-13.79%30.39%64.6%-63.13%19.45%741.5%-175.54%3.98%306.86%-140.92%348.19%-46.44%194.8%-55.11%-73.38%150.28%26.77%22.82%147199.86%-88.41%280.13%-
Book Value per Share1.180.392.810.621.211.341.070.641.731.50-0.250.340.34-0.180.440.110.220.080.190.780.370.360.420.000.020.02
Total Shareholders' Equity143.54M48.81M363.82M83.81M169.8M196.95M151.05M91.77M248.89M208.37M-32.48M43M41.35M-19.99M48.85M10.9M20.35M6.9M15.38M57.77M23.08M18.21M14.82M10.06K86.81K22.84K
Common Stock114K118K123K127K135K138K135K137K145K143K130K128K126K114.53K112.71K103.99K100.58K91.68K81.55K77.9K68.74K60.25K49.2K8.2K1.92K1.28K
Retained Earnings151.26M54.79M359.87M90.55M143.22M-58.91M-474.59M-603.68M-531.44M-522.37M-585.34M-482.66M-450.43M-382.05M-298.57M-245.02M-225.25M-172.01M-113.65M-65M-41.1M-26.35M-13.07M-184.01K-104.92K-39.65K
Treasury Stock00000000000000000000000000
Accumulated OCI-7.83M-18.09M3.83M-9.28M-922K-620K22K240K-277K-450K-6K-99K-41K17.05K-6.68M-5.75M-4.68M-3.45M-2.04M-1.03M-704.55K-532.01K-332.24K000
Minority Interest00000000000000000000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrong
Balance SheetStrained
Cash FlowRobust
Top Statement Risk

High leverage from acquisition debt

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Leverage Surge Masks Underlying Strength

Total debt jumped from $1.5B to $2.1B in 2025Q4, while equity swung to $48.8M, per latest filings, indicating a debt-funded acquisition that has strained the balance sheet despite robust cash generation.

The balance sheet has shifted from a conservative structure in early 2025 to a highly leveraged one by 2026Q2, with debt-to-equity soaring to 14.95. This appears to be a strategic move to fund a major acquisition, as evidenced by the $1.0B acquisition outflow in 2025Q4. While operating cash flow remains robust, the increased leverage raises the risk profile and may constrain future financial flexibility.

Debt-Fueled Expansion Elevates Leverage

Total debt rose to $2.1B in 2026Q2, pushing D/E to 14.95, as reported in financial statements, reflecting a deliberate shift to debt financing for growth, which now demands close monitoring of cash flow coverage.

The debt increase of $600M in 2025Q4 aligns with the acquisition activity, suggesting a strategic use of leverage to expand capabilities. However, with equity only $143.5M, the balance sheet is highly leveraged, and any earnings shortfall could amplify financial risk. The company's robust operating cash flow, which exceeded $1.5B cumulatively, provides some comfort, but investors should monitor debt covenants and refinancing needs.

Asset-Light Model with Rising Intangibles

Goodwill rose to $581.7M in 2026Q2 from $416.8M in 2025Q3, per SEC filings, indicating acquisition-driven intangibles, while PPE remains minimal at $84.3M, underscoring the asset-light royalty model.

The increase in goodwill and intangibles reflects the acquisition, which may carry impairment risk if expected synergies fail to materialize. The low PPE relative to total assets confirms the asset-light nature of the business, where value is derived from intellectual property and partnerships rather than physical assets. This mix suggests that the balance sheet's quality hinges on the performance of acquired assets.

Equity Eroded by Buybacks and Charges

Equity fell to $143.5M in 2026Q2 from $503.9M in 2025Q3, as per quarterly reports, driven by aggressive buybacks and a one-time loss, highlighting a shrinking equity base despite strong earnings.

The dramatic decline in equity is attributed to $332.7M in buybacks in 2026Q2 and a net loss in 2025Q4, which reduced retained earnings. While buybacks signal confidence, they also deplete the equity cushion, increasing financial leverage. The negative retained earnings in 2025Q4 suggest a significant non-operating charge, warranting scrutiny of its nature and recurrence.

Liquidity Buffer Thins Despite High Ratio

Current ratio remains strong at 2.71 in 2026Q2, but cash dropped to $163.1M from $309.7M in 2026Q1, as reported, indicating a thinner liquidity buffer relative to increased debt obligations.

The current ratio is healthy, but the absolute cash position has declined significantly, partly due to buybacks and debt servicing. With total debt at $2.1B, the cash balance covers only a small fraction of debt, suggesting reliance on operating cash flow to meet obligations. The company's robust cash generation provides a buffer, but the reduced cash reserves increase vulnerability to short-term shocks.

Acquisition Debt Distorts Leverage Metrics

The $600M debt increase in 2025Q4, per cash flow statements, appears tied to an acquisition, making headline D/E of 14.95 misleading as it reflects a one-time event rather than ongoing operational leverage.

The sharp rise in leverage is not indicative of deteriorating operations but rather a strategic financing decision. Investors should assess the acquired assets' contribution to future cash flows to determine if the debt is justified. The absence of deferred revenue suggests no visibility into future obligations, but the acquisition's success is critical to balance sheet health.

HALO — Frequently Asked Questions

Quick answers to the most common questions about buying HALO stock.

What are the total assets of Halozyme Therapeutics, Inc. (HALO)?

As of 2025, Halozyme Therapeutics, Inc. (HALO) had total assets of $2.53B including $825.2M in current assets.

How much debt does Halozyme Therapeutics, Inc. (HALO) have?

Halozyme Therapeutics, Inc. (HALO) carries total debt of $2.14B, offset by $142.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Halozyme Therapeutics, Inc.?

Halozyme Therapeutics, Inc. (HALO) has total shareholders' equity (book value) of $48.8M ($0.39 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Halozyme Therapeutics, Inc.'s current ratio and liquidity?

Halozyme Therapeutics, Inc. (HALO) reported a current ratio of 4.66x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.